The National Institute of Health, Clinical Center (CC) intends to award a fixed price purchase order to BioArray Solutions LTD, Warren NJ, 07059 on a sole source basis to procure reagents that has been quality controlled for use on the existing government-owned BioArray AIS Imaging 4000 system used to perform genotyping for RBC (Red Blood Cell) blood groups for the CC.

BioArray Solutions LTD, a subsidiary of Immucor Inc., is the sole manufacturer and trademark holder for the Bioarray^TM BeadChip ^TM select proprietary reagents to be used with the BioArray test platform, including the AIS reader and software to perform, analyze and report the genotype and predicted phenotype of red blood cell blood group antigens. The BioArray Beadchip assay platform is the only FDA approved test system for performing molecular genotyping for RBC antigens. It has been validated according to regulatory requirements and is used in the Department of Transfusion Medicine to perform these tests on patients and blood donors in order to provide the best matched blood for transfusion, thereby improving patient safety and outcomes.

The comprehensive system of instruments and consumables is necessary to produce a complete typing result. The following supply list is required:

Item#                       Description                                                    Quantity
800-00202-08   HEA 1.2 Beadchip kit 12 x 8 slide; 96 tests/kit        1
800-00206-48   RHCE Beadchip kit 6 x 8; 48 tests/kit                       2
800-00220-48   RHD Beadchip kit 6 x 8; 48 tests/kit                          2
800-20236         BeadCheck HEA DNA reference panel                     1

This acquisition is being conducted under the authority of the FAR Subpart 13.106-1(b)(i), Contracting officers may solicit from one source if the contracting officer determines that the circumstances of the contract action deem only one source reasonably available. Interested concerns capable of providing the same or similar products or services as described in this notice may submit a capability statement outlining their capabilities. Capability Statements must be received within the time set forth in this synopsis to be considered by the Government. A determination to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.

Each response should include the following Business Information:
a. DUNS.
b. Company Name, address, POC, Phone and Email address
c. Current GSA Schedules or NAICS codes appropriate to this Award.
d. Type of Company (i.e., small business, 8(a), woman owned, hubZone, veteran owned, etc.) as validated in System For Award Management (SAM). All offerors must register on the SAM located at http://www.sam.gov/portal/SAM/#1
e. Capability Statement

Comments to this announcement may be submitted to the Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, electronically to the attention of Malinda Dehner, Contract Specialist, [email protected] by the due date and time marked in this notice.